Microtubules are important components of the cytoskeleton that forms the backbone of myocardial architecture, sustaining its form and size. This study investigated whether stabilizing microtubules with paclitaxel (0.1 or 1 µM) could decrease myocardial ischaemiareperfusion injury, and reduce myocardial infarct size and the incidence of ischaemic ventricular arrhythmia. Isolated rat hearts were used, with arrhythmia induced by regional ischaemia and myocardial infarcts induced by ischaemia-reperfusion. In these ex vivo rat models, paclitaxel decreased myocardial ischaemia-reperfusion injury, significantly reducing the incidence and severity of ischaemic ventricular arrhythmia and significantly decreasing infarct size.
Introduction
Globally, the morbidity and mortality associated with coronary heart disease remains high. 1 Ischaemia is the most common cause of ventricular arrhythmia, 1 -3 and the emergence of ventricular arrhythmia aggravates clinical symptoms and leads to deterioration of the disease. 4 The control of ventricular arrhythmia and cardioprotection after ischaemia are, therefore, becoming increasingly important aspects of cardiac research and therapy. 5 -7 Ischaemic ventricular arrhythmia is often caused by ischaemia-induced cell dysfunction or abnormal ion flow. 1, 3 Maintaining cell structure and function can reduce the occurrence of ventricular arrhythmia. 1, 3 Microtubules are conserved structures, primarily composed of tubulin, and a dynamic equilibrium exists between free tubulin and polymerized tubulin. 8, 9 Microtubules support cellular architecture, plasma membranes, myofibrils and other cellular organelles via their filamentous network, and provide pathways for transporting mitochondria, endoplasmic reticulum and other membranous organelles throughout the cell. 10 Microtubules also play a role in the compartmentalization and anchoring of many proteins, including receptors and ion channels. Microtubule integrity is important in cardioprotection. Disruption of microtubules can inhibit the protective effects of ischaemic preconditioning and isoflurane-induced myocardial preconditioning. 11, 12 It is not known whether stabilizing microtubules can reduce the size of myocardial infarct and a H-M Cao and Q Wang contributed equally to this work. Stabilizing microtubules decreases myocardial injury ventricular arrhythmia associated with ischaemia-reperfusion injury.
Paclitaxel is a microtubule stabilizer that promotes tubulin polymerization and stabilizes existing microtubules. The present study investigated the effect of paclitaxel in a rat ex vivo model of myocardial infarction and ischaemic ventricular arrhythmia associated with ischaemia-reperfusion injury. 
Materials and methods

ANIMALS
RAT MODELS
Ventricular arrhythmia model
Rats were killed by stunning and cervical dislocation. Each heart was rapidly removed and placed in ice-cold Krebs-Henseleit (K-H) buffer (118.0 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 25 mM NaHCO 3 , 1.2 mM MgSO 4 , 2.5 mM CaCl 2 , 11.0 mM glucose, pH 7.35 -7.45). The heart was then mounted onto a Langendorff apparatus and perfused at a constant pressure of 75 mmHg, with K-H buffer gassed with 95% O 2 /5% CO 2 , equilibrated at pH 7.35 -7.45 and maintained at 37°C for 20 min. 13 -15 These conditions represent normoxic superfusion.
Ischaemia was induced in the isolated hearts by coronary artery ligation with a 3-0 surgical suture. The left main coronary artery was ligated within 2 mm of where it emerged adjacent to the left atrium, for 30 min.
Coronary flow rate was monitored before and during ligation, with successful ligation indicated by a ≥ 25% reduction in coronary flow. After 30 min, 2,3,5-triphenyltetrazolium chloride (TTC) staining was undertaken, to check for necrosis. 16
Myocardial infarction model
The myocardial infarction model was established, as described previously. 17 The isolated hearts were rapidly mounted onto a Langendorff apparatus and perfused with K-H buffer (as described above). Following ischaemia (induced by ligation of the left main coronary artery for 30 min), reperfusion was achieved by releasing the ligation, which caused myocardial infarction.
STABILIZATION OF MICROTUBULES
Paclitaxel 0.1 µM or 1 µM (Taxol ® ; Sigma-Aldrich, St Louis, MO, USA) was used to stabilize the microtubules. 18 It was dissolved in dimethylsulphoxide then added into the perfusate and diluted to different concentrations (0.1 or 1 µM).
ASSESSMENT OF ARRHYTHMIA
To assess the effect of paclitaxel on arrhythmia, 60 isolated hearts were divided into four groups: control group; ischaemia group; ischaemia + paclitaxel (0.1 µM) group; ischaemia + paclitaxel (1 µM) group. After a 15-min equilibration period, the control group received 50 min of normoxic superfusion, the ischaemia group received 20 min of normoxic superfusion followed by 30 min of ischaemia, and both ischaemia + paclitaxel groups received 20 min of normoxic superfusion followed by 30 min of ischaemia, with paclitaxel (0.1 or 1 µM) administered throughout the entire 50-min period.
Arrhythmia was determined and diagnosed in accordance with the Lambeth Convention criteria. 14 Each heart was given Stabilizing microtubules decreases myocardial injury a score that represented the most severe type of arrhythmia observed during the entire 50min study period: 0, no arrhythmia; 1, occasional ventricular premature beats (VPB); 2, frequent VPBs (three or more within 1 min); 3, ventricular tachycardia (VT, one or two episodes); 4, VT (three to five episodes); 5, VT (more than five episodes); 6, ventricular fibrillation (VF, one or two episodes); 7, VF (three to five episodes); and 8, VF (more than five episodes).
Experiments were terminated or excluded if any of the following occurred: absence of signs of successful coronary artery occlusion (< 25% reduction in coronary flow); severe arrhythmia prior to coronary artery occlusion; or severe atrioventricular block during the first 5 min of ischaemia.
MEASUREMENT OF INFARCT SIZE
To assess the effect of paclitaxel on infarct size, a further 16 isolated hearts were divided into two groups (n = 8 per group): the control group (ischaemia-reperfusion group) and the paclitaxel group. After a 15-min equilibration period, both groups received 30 min of ischaemia and 120 min of normoxic reperfusion.
The paclitaxel group additionally received paclitaxel (1 µM) via perfusion throughout the entire 150-min period. To determine infarct size, the left main coronary artery was re-ligated at the end of reperfusion and 2.5% Evans blue was perfused. The blue-stained region was regarded as the risk area and was removed. The remainder was frozen and cut into sections of 2 -3 µm in thickness, which were incubated in phosphate-buffered saline (137 mmol/l NaCl, 2.7 mmol/l KCl, 10 mmol/l Na 2 HPO 4 , 2 mmol/l KH 2 PO 4 ; pH 7.35 -7.45) containing TTC (1% w/v) for 15 min, to visualize the infarct area. The infarcted region was weighed and expressed as a percentage of the risk area.
STATISTICAL ANALYSES
Quantitative data are expressed as the mean ± SE. All analyses were performed using the SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Timedependent data were subjected to two-way analysis of variance to determine whether there were any significant differences among the groups. In addition, paired t-test, χ 2 -test or one-way analysis of variance were conducted to analyse one-way layout data where appropriate. A P-value < 0.05 was considered to be statistically significant.
Results
After 30 min, TTC staining confirmed there was no necrosis, following induction of ischaemia in the isolated hearts.
Stabilizing microtubules with paclitaxel reduced ischaemic ventricular arrhythmia. Compared with the ischaemia group, paclitaxel (0.1 or 1 µM) effectively reduced the severity of ischaemic ventricular arrhythmia in a dose-dependent fashion: arrhythmia scores were reduced and the incidence of VT decreased. Compared with the ischaemia group, arrhythmia scores were reduced by 47% (paclitaxel 0.1 µM) and 92% (paclitaxel 1 µM) (P < 0.05) (Fig. 1) . The incidence of VT decreased to 40% (paclitaxel 0.1 µM) and 13% (paclitaxel 1 µM) (P < 0.05) compared with 80% in the ischaemia group (Fig. 2) .
Stabilizing microtubules with paclitaxel decreased the infarct size. Fig. 3 depicts typical myocardial infarcts. Paclitaxel 1 µM significantly reduced the infarct size, compared with ischaemia-reperfusion alone (P < 0.05) (Fig. 4 ).
Discussion
The present study demonstrated that stabilizing microtubules effectively protected cardiac myocytes from ischaemia-Stabilizing microtubules decreases myocardial injury reperfusion injury, and reduced the incidence and severity of ischaemic ventricular arrhythmia. Furthermore, infarct size was significantly reduced.
Myocardial ischaemia-reperfusion injury is a multifactorial process, mediated in part by oxygen-derived free radicals and intracellular calcium overload. The primary of such injury are arrhythmias, contractile dysfunction and myocyte death. 1,19 -21 Microtubules are an important component of the cellular cytoskeleton that forms the backbone of myocardial architecture, sustaining its form and size. The present study showed that stabilizing the microtubules in the ex vivo rat model of cardiac ischaemia or ischaemia-reperfusion injury significantly reduced ischaemic ventricular arrhythmia and infarct size. If these findings can be transferred to humans, they may demonstrate potential clinical benefits. The study was, however, limited as it was based on animal tests that cannot be applied directly to clinical practice. Thus, future studies are needed to determine the clinical The mechanisms underlying the acute protection from cardiac ischaemiareperfusion injury observed in the present study are unknown. Previous studies have found that calcium overload and transient alterations in calcium play important roles in arrhythmia. 22 -24 Stabilizing microtubules may, therefore, reduce the generation of (or resist injury due to) oxygen-derived free radicals, or reduce intracellular Ca 2+ overload. These hypotheses warrant further investigation.
In conclusion, the present study demonstrated that stabilizing microtubules decreased myocardial ischaemia-reperfusion injury, ameliorated ischaemic ventricular arrhythmias and reduced infarct size in ex vivo rat models. Stabilizing microtubules may, therefore, represent a potential therapeutic approach for cardiac ischaemiareperfusion injury.
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